Chugai Pharmaceutical Co (MEX:4519N) Beneish M-Score: -2.27 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:4519N Chugai Pharmaceutical Co Ltd MEX:4519N
97 GF Score
Price MXN825.61
GF Value MXN873.09
! 1 Warning Sign
View Full Analysis

What is Chugai Pharmaceutical Co Beneish M-Score?

Chugai Pharmaceutical Co MEX:4519N 97 Beneish M-Score is -2.27 as of Jul. 21, 2026. GuruFocus rates MEX:4519N with a GF Score™ of 97/100 and a GF Value™ of MXN873.09. The stock has 1 warning sign investors should review. Among 910 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks worse than 66.92% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.27 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Chugai Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

MEX:4519N' s Beneish M-Score Range Over the Past 10 Years
Min: -3.02   Med: -2.37   Max: -1.65
Current: -2.27

During the past 13 years, the highest Beneish M-Score of Chugai Pharmaceutical Co was -1.65. The lowest was -3.02. And the median was -2.37.


Chugai Pharmaceutical Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Chugai Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chugai Pharmaceutical Co Beneish M-Score Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.11 -1.74 -3.02 -2.59 -2.04

Chugai Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.23 -2.59 -2.32 -2.04 -2.27

MEX:4519N vs LLY, JNJ, ABBV: Beneish M-Score Comparison

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chugai Pharmaceutical Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Beneish M-Score falls into.


MEX:4519N
97GF Score
Chugai Pharmaceutical Co Ltd MEX:4519N
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chugai Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Chugai Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.023+0.528 * 0.9944+0.404 * 1.4451+0.892 * 0.9688+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0414+4.679 * 0.004837-0.327 * 1.4851
=-2.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was MXN40,086 Mil.
Revenue was 36563.325 + 39992.252 + 41334.555 + 37793.673 = MXN155,684 Mil.
Gross Profit was 26018.671 + 29880.581 + 28898.682 + 26316.454 = MXN111,114 Mil.
Total Current Assets was MXN174,942 Mil.
Total Assets was MXN257,406 Mil.
Property, Plant and Equipment(Net PPE) was MXN54,738 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN0 Mil.
Selling, General, & Admin. Expense(SGA) was MXN14,711 Mil.
Total Current Liabilities was MXN37,240 Mil.
Long-Term Debt & Capital Lease Obligation was MXN0 Mil.
Net Income was 13116.1 + 14829.31 + 13797.332 + 12661.314 = MXN54,404 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = MXN0 Mil.
Cash Flow from Operations was 13868.624 + 14909.803 + 8819.459 + 15561.211 = MXN53,159 Mil.
Total Receivables was MXN40,445 Mil.
Revenue was 39591.084 + 40958.116 + 43481.081 + 36662.372 = MXN160,693 Mil.
Gross Profit was 27537.351 + 28171.696 + 31881.003 + 26456.684 = MXN114,047 Mil.
Total Current Assets was MXN208,127 Mil.
Total Assets was MXN293,645 Mil.
Property, Plant and Equipment(Net PPE) was MXN63,630 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN0 Mil.
Selling, General, & Admin. Expense(SGA) was MXN14,581 Mil.
Total Current Liabilities was MXN28,607 Mil.
Long-Term Debt & Capital Lease Obligation was MXN0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(40086.165 / 155683.805) / (40444.506 / 160692.653)
=0.257484 / 0.251689
=1.023

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(114046.734 / 160692.653) / (111114.388 / 155683.805)
=0.70972 / 0.713718
=0.9944

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (174942.056 + 54737.995) / 257406.049) / (1 - (208126.626 + 63630.062) / 293644.542)
=0.107713 / 0.074539
=1.4451

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=155683.805 / 160692.653
=0.9688

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 63630.062)) / (0 / (0 + 54737.995))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(14710.949 / 155683.805) / (14581.074 / 160692.653)
=0.094492 / 0.090739
=1.0414

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 37240.051) / 257406.049) / ((0 + 28606.942) / 293644.542)
=0.144674 / 0.09742
=1.4851

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(54404.056 - 0 - 53159.097) / 257406.049
=0.004837

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Chugai Pharmaceutical Co has a M-score of -2.45 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.27 mean?
Chugai Pharmaceutical Co (MEX:4519N) has a Beneish M-Score of -2.27 as of Jul. 21, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Chugai Pharmaceutical Co and its competitors. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #609 out of 910 companies in the Drug Manufacturers industry, placing it in the top 66.9%.
Is Chugai Pharmaceutical Co's Beneish M-Score too high?
Chugai Pharmaceutical Co's current Beneish M-Score is -2.27. Based on the distribution chart, Chugai Pharmaceutical Co ranks #609 out of 910 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Chugai Pharmaceutical Co has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Beneish M-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #609 out of 910 companies for Beneish M-Score. This places Chugai Pharmaceutical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Chugai Pharmaceutical Co and its competitors. Chugai Pharmaceutical Co's current Beneish M-Score is -2.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Chugai Pharmaceutical Co (MEX:4519N) has a current Beneish M-Score of -2.27. The stock's GF Value™ is MXN873.09, compared to a current price of MXN825.61 — trading 5.4% below its estimated fair value. The current Beneish M-Score is -2.27. Chugai Pharmaceutical Co's overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Chugai Pharmaceutical Co (MEX:4519N), the current Beneish M-Score is -2.27 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chugai Pharmaceutical Co (MEX:4519N) Overvalued in 2026?

Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued. The current stock price of MXN825.61 is trading 5.4% below its estimated GF Value™ of MXN873.09.

Key valuation signals for MEX:4519N:

  • Beneish M-Score: -2.27
  • GF Value™: MXN873.09 vs. price of MXN825.61 (5.4% below fair value)
  • GF Score™: 97/100 with 1 warning sign

No single metric tells the full story. See the MEX:4519N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chugai Pharmaceutical Co Business Description

Address 2-1-1 Muromachi, Nihonbashi, 12th Floor, Nihonbashi Mitsui Tower, Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
97GF Score

Get the complete analysis for MEX:4519N

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN825.61
Price
MXN873.09
GF Value